Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics
Authors:
Open Access
- 31 January 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 9, 753
Abstract
Schizophrenia is considered a syndrome comprised by several disease phenotypes, covering a range of underlying pathologies. One of these disease mechanisms seems to involve immune dysregulation and neuroinflammation. While the current dopamine receptor-blocking antipsychotic drugs decrease psychotic symptoms and prevent relapse in the majority of patients with schizophrenia, there is a huge need to explore new treatment options that target other pathophysiological pathways. Such studies should aim at identifying robust biomarkers in order to diagnose and monitor the immune biophenotype in schizophrenia and develop better selection procedures for clinical trials with anti-inflammatory and immune-modulating drugs. In this focused review, we describe available methods to assess inflammatory status and immune disturbances in vivo. We also outline findings of immune disturbances and signs of inflammation at cellular, protein, and brain imaging levels in patients with schizophrenia. Furthermore, we summarize the results from studies with anti-inflammatory or other immune-modulating drugs, highlighting how such studies have dealt with participant selection. Finally, we propose a strategy to construct an immune signature that may be helpful in selecting and monitoring participants in studies with immune modulating drugs and also applicable in regular clinical work.Keywords
This publication has 133 references indexed in Scilit:
- Neuroinflammation and psychiatric illnessJournal of Neuroinflammation, 2013
- Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trialTrials, 2013
- Excessive Extracellular Volume Reveals a Neurodegenerative Pattern in Schizophrenia OnsetThe Journal of Neuroscience, 2012
- Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulnessTherapeutic Advances in Chronic Disease, 2012
- The translocator protein ligand [18F]DPA-714 images glioma and activated microglia in vivoEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouseSchizophrenia Research, 2011
- Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control studyBMC Psychiatry, 2011
- IL-17 and Th17 CellsAnnual Review of Immunology, 2009
- Immunological and Inflammatory Functions of the Interleukin-1 FamilyAnnual Review of Immunology, 2009
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999